Cochlear (ASX:COH) is one of Australia’s shining examples of technical adroitness and export attractiveness, an example to entrepreneurs of what can be achieved in Australia despite punitive wages and regulation. Show More
cochlear
COH’s total sales revenue increased by 12% in constant currency (CC) to $1,239.7 million in 2017, while total expenses rose by 10% in CC to $942.7 million. As a result EBIT rose 15% in CC to $315.6 million. The net profit result includes $20.0 million of currency translation impacts... Show More
Warren Buffett famously favours companies with strong competitive moats. A look at his results investing in Coca-Cola and See’s Candies, it’s not hard to see why. Moats exist everywhere, but not all are created equal. Large, global companies are sometimes able to create a moat so strong that it can... Show More
Global hearing implant maker Cochlear Limited (COH), issued a 19% lift in first half profit. Cochlear implant sales rose 10%, while revenue lifted by 4% over the half For more Reporting Season coverage, please visit https://www.commsec.com.au/reportingseason Show More
The healthcare industry is always evolving, and new therapies drive ongoing growth over and above the growth from the ageing demographic. However, it’s important that investors recognise that the sector’s growth doesn’t necessarily translate equally to each participant, for example, when new therapies displace incumbents. Three particular drivers of change... Show More
Manufacturer and distributor of hearing implantable devices, Cochlear Limited (COH), reported a strong full year result even with net profit just under market expectations For more Reporting Season coverage, please visit https://www.commsec.com.au/reportingseason Show More
Cochlear (COH) posted a better than expected 32% lift in first half profit to $94 million. The result was boosted mostly by a weaker Australian dollar which has helped lift global revenue For more Reporting Season coverage, please visit https://www.commsec.com.au/reportingseason Show More
Cochlear shares took a step back this week following an underwhelming full year profit report. While the business continues to grow, the market expected more, and some scale back of FY16 expectations was required. Having looked at Cochlear recently, we think that it may be a victim of its own... Show More
Cochlear (COH) posted a weaker than expected $145.8m profit for the 12 months ended June 2015. Sales at the world’s largest maker of inner-ear hearing implants also fell short of consensus . For more Reporting Season coverage, please visit https://www.commsec.com.au/reportingseason Show More
Cochlear (COH, Reduce, Price Target A$79.93) - An AFR article out last week highlights growing competition for cochlear implants (CIs) in China, with COH optimistic its product innovation and sector growth, especially in the ageing adult market, will allow it to offset these competitive threats and drive sales. Although shares... Show More
Jeremy Benson, StocksInValue Client Advisor took the opportunity to speak to John Abernethy to gain his insight on the latest reporting season before he headed overseas. From the reporting season there were large price movements in reaction to company announcements, particularly stocks that were shorted. Shorting activity contributed to Cochlear's... Show More
Cochlear $COH Announced at 2am Sydney Time. The FDA Clearance Of The Baha(R) 4 Attract System, The First Magnetic Baha Bone Conduction Hearing Device Show More